Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ReNeuron establishes Boston office ahead of US clinical trials

It will be a base for medical and scientific communications staff
Boston skyline
Boston is one of the US's most vibrant academic and commercial biotechnology hubs

Stem cell therapy specialist ReNeuron Group Plc (LON:RENE) said it is opening an office in Boston, Massachusetts, in order to support planned clinical programmes.

It will be a base for medical and scientific communications staff ahead of three phase IIb trials in the US of its CTX and hRPC cell therapy candidates in people recovering from strokes and patients with retinal diseases.

READ: ReNeuron making good progress with all of its key therapeutic programmes

Having a presence Stateside will allow ReNeuron to more closely manage its relationship with the clinical research organisations carrying out the studies, the company said.

It will also allow the UK research group to establish stronger ties with key opinion leaders in America, it added.

"We are delighted to have established operations in Boston, one of the US's most vibrant academic and commercial biotechnology hubs,” said Olav Hellebø, chief executive. 

WATCH: ReNeuron's Michael Hunt discusses very encouraging long-term stroke data

“The US is a major future market for our cell-based therapies and a presence on the ground represents a key element of ReNeuron's clinical and commercial development strategy as our therapeutic candidates move closer to market." 

View full RENE profile View Profile

ReNeuron Group Plc Timeline

Related Articles

1519933435_to-conceive-pic.jpg
March 01 2018
The health and wellbeing group, which has a broad product portfolio, had an eventful 2017,
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
little girl sneezing in a field
Mon
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use